IBI311 not checked

Innovent

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Thyroid Eye Disease
Main trialPhase 3
“A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.”In the company’s words, NCT07113262 on ClinicalTrials.gov

Other drugs for Thyroid Eye Disease

All 17 drugs for Thyroid Eye Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2026 A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Phase 3Completed 23 Sep 2025 A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
Phase 2/3Completed 20 Dec 2023 A Study of IBI311 in Subjects With Active Thyroid Eye Disease
Phase 2Completed 9 Jan 2025 A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
Phase 1Completed 23 Nov 2022 A Study of IBI311 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IBI311

Following is part of Solo: you see every change to IBI311 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in